Taxotere approved for prostate cancer
Executive Summary
Aventis' Taxotere (docetaxel) adds indication for treatment of hormone refractory prostate cancer in combination with prednisone May 19. Revised 1labeling includes data from 335 patients showing median survival advantage of 2.4 months versus mitoxantrone (Amgen/OSI's Novantrone). Taxotere is first drug to show survival benefit in that population, FDA says. Aventis is also investigating Taxotere as first-line prostate cancer therapy...
You may also be interested in...
Aventis Taxotere Approved For Breast Cancer; Lowers Relapse Chance 25.7%
Aventis added an adjuvant node-positive breast cancer indication for Taxotere Aug. 18
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.